Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 3526 - 3550 of 4207 in total
Vactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).
Investigational
Glumetinib is under investigation in clinical trial NCT04270591 (Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced C-met-positive Non-small Cell Lung Cancer).
Investigational
Investigational
Investigational
Pyrifazimine is under investigation in clinical trial NCT04670120 (Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)).
Investigational
TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson Disease).
Investigational
Efonidipine is a calcium channel blocker of the dihydropyridine class, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, Landel. The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis...
Experimental
(1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is a solid. This compound belongs to the indole-3-acetic acid derivatives. These are compounds containing an acetic acid (or a derivative) linked to the C3 carbon atom of an indole. (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is known to target interleukin-2.
Experimental
3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide is a solid. This compound belongs to the phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond. This drug targets mitogen-activated protein kinase 14.
Experimental
Investigational
Displaying drugs 3526 - 3550 of 4207 in total